ONC Latest Headlines

BeOne Medicines Ltd (6160) Gets a Buy from CICC

at www.tipranks.com (Thu, 4-Jun 9:48 PM)

BeOne Medicines Rocked by Fresh Insider Stock Sale From Boardroom Heavyweight

at www.tipranks.com (Wed, 3-Jun 10:06 PM)

Citi Keeps Their Buy Rating on BeOne Medicines Ltd (6160)

at www.tipranks.com (Wed, 3-Jun 8:26 PM)

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC)

at www.tipranks.com (Wed, 3-Jun 2:00 PM)

BeOne Medicines Halts Early KRAS Trial, Resetting Expectations in a Crowded Oncology Race

at www.tipranks.com (Wed, 3-Jun 12:31 PM)

Zymeworks and BeOne: Long-Term Cancer Study Update Supports Durable Drug Story

at www.tipranks.com (Wed, 3-Jun 12:31 PM)

Most and least shorted mid- to mega-cap healthcare stocks at the end of May

at seekingalpha.com (Wed, 3-Jun 9:35 AM)

Wolfe Research Sticks to Its Buy Rating for BeOne Medicines (ONC)

at www.tipranks.com (Wed, 3-Jun 8:40 AM)

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

at www.tipranks.com (Wed, 3-Jun 4:17 AM)

Analysts Conflicted on These Healthcare Names: BeOne Medicines (ONC), Moderna (MRNA) and Danaher (DHR)

at www.tipranks.com (Tue, 2-Jun 9:00 AM)

TD Cowen Remains a Buy on BeOne Medicines (ONC)

at www.tipranks.com (Tue, 2-Jun 8:58 AM)

Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines (ONC) and Autonomix Medical, Inc. (AMIX)

at www.tipranks.com (Tue, 2-Jun 8:41 AM)

ONC's Phase 3 HERIZON-GEA Study Shows Seven-Month Survival Gain in HER2+ Gastroesophageal Cancer

Market Chameleon (Thu, 28-May 7:08 AM)

BeOne Medicines Showcases Over 60 Abstracts at ASCO and EHA 2026, Cementing Leadership in CLL and Expanding its Solid Tumor Pipeline

Market Chameleon (Thu, 21-May 7:10 AM)